^
Association details:
| Biomarker: | EGFR amplification |
|---|---|
| Cancer: | Esophageal Squamous Cell Carcinoma |
| Drug: | larotinib (Z650) (pan-HER inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
Published date:
10/23/2021
Excerpt:
The investigator-assessed overall response rate (ORR) was 13.7% (10/73), all responses were observed in the 350 mg group of which ORR up to 20.0% (10/50), with 10 of them having EGFR overexpression and 4 having EGFR amplification....Larotinib demonstrated promising antitumor activity and manageable safety profiles in patients with pre-treated advanced ESCC with EGFR overexpression or amplification, especially at the dose of 350 mg, which showed better efficacy and acceptable safety.
DOI:
https://doi.org/10.1186/s12876-021-01982-4
Trial ID:
